Literature DB >> 23559909

Thrombolysis in the age of Primary Percutaneous Coronary Intervention: Mini-Review and Meta-analysis of Early PCI.

O Al Shammeri1, LA Garcia.   

Abstract

OBJECTIVE: Primary Percutaneous Coronary Intervention (PCI) is the treatment of choice for ST-segment Elevation Myocardial Infarction (STEMI) if performed within 90 minutes from first medical contact. However, primary PCI is only available for less than 25% of patients with STEMI. Early PCI or Pharmaco-invasive strategy has evolved from facilitated PCI but with more delayed timing from thrombolysis to PCI. AIM: Assess the safety and effectiveness of Early PCI. PATIENTS AND
METHOD: We reviewed the data of the available therapy options for patients with STEMI. Then we performed a meta-analysis for all randomized controlled trials of early PCI versus standard therapy.
RESULTS: Five studies fulfilled our inclusion criteria. Our meta-analysis showed improved cardiovascular events with early PCI compared to standard therapy (odd ratio of 0.54; 95% Confidence interval 0.47-0.7, p<0.001). There were no significant bleeding complications when doing early PCI 4 to 24 hours after successful thrombolysis.
CONCLUSION: Early PCI should be done to all STEMI patients within 24 hours after successful thrombolysis.

Entities:  

Keywords:  Acute myocardial infarction; Early PCI; Pharmacoinvasive strategy; Thrombolysis

Year:  2013        PMID: 23559909      PMCID: PMC3612420          DOI: 10.12816/0006026

Source DB:  PubMed          Journal:  Int J Health Sci (Qassim)        ISSN: 1658-3639


  25 in total

Review 1.  Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting.

Authors:  C M Gibson
Journal:  Ann Intern Med       Date:  1999-05-18       Impact factor: 25.391

2.  Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?

Authors:  Brahmajee K Nallamothu; Eric R Bates
Journal:  Am J Cardiol       Date:  2003-10-01       Impact factor: 2.778

3.  Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients.

Authors:  D B Altmann; M Racz; D S Battleman; G Bergman; A Spokojny; E L Hannan; T A Sanborn
Journal:  Am Heart J       Date:  1996-09       Impact factor: 4.749

4.  Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis.

Authors:  Brahmajee K Nallamothu; Eric R Bates; Jeph Herrin; Yongfei Wang; Elizabeth H Bradley; Harlan M Krumholz
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

5.  Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial.

Authors:  Francisco Fernandez-Avilés; Joaquín J Alonso; Alfonso Castro-Beiras; Nicolás Vázquez; Jesús Blanco; Juan Alonso-Briales; Juan López-Mesa; Felipe Fernández-Vazquez; Isabel Calvo; Luis Martínez-Elbal; José A San Román; Benigo Ramos
Journal:  Lancet       Date:  2004 Sep 18-24       Impact factor: 79.321

6.  Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.

Authors:  Bruno Scheller; Benno Hennen; Bernd Hammer; Jürgen Walle; Christian Hofer; Volker Hilpert; Horst Winter; Georg Nickenig; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

Review 7.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

8.  Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction).

Authors:  Ellen Bøhmer; Pavel Hoffmann; Michael Abdelnoor; Harald Arnesen; Sigrun Halvorsen
Journal:  J Am Coll Cardiol       Date:  2009-09-10       Impact factor: 24.094

9.  The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.

Authors:  D P de Bono
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

10.  Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.

Authors: 
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

View more
  5 in total

1.  Barriers to the implementation of prehospital thrombolysis in the treatment of ST-segment elevation myocardial infarction in South Africa: An exploratory inquiry.

Authors:  Andrew Lynch; Simpiwe Sobuwa; Nicholas Castle
Journal:  Afr J Emerg Med       Date:  2020-09-03

Review 2.  Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis.

Authors:  Feng Liu; Qinglong Guo; Guoqiang Xie; Han Zhang; Yaxi Wu; Lixia Yang
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240

3.  Effects of remote ischemic post-conditioning on platelet activation of AMI patients.

Authors:  Yun-Xia Qian; Ke-Sheng Dai; Li-Li Zhao; Xiang-Jun Yang
Journal:  Exp Ther Med       Date:  2018-06-08       Impact factor: 2.447

4.  Factors associated with quality of life in patients undergoing coronary angioplasty.

Authors:  Azar Darvishpour; Nazila Javadi-Pashaki; Arsalan Salari; Tahere Sadeghi; Marayam Taleshan-Nejad
Journal:  Int J Health Sci (Qassim)       Date:  2017 Sep-Oct

5.  Cardiac Regeneration: New Insights Into the Frontier of Ischemic Heart Failure Therapy.

Authors:  Andrew S Riching; Kunhua Song
Journal:  Front Bioeng Biotechnol       Date:  2021-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.